This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on
providing the best care and treatment for people with atrial fibrillation, including assessing and
managing risks of stroke and bleeding.
The recommendations in this guideline were developed before the CO...
This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.
The recommendations in this guideline were developed before the C...
A clinical summary of this KDP was published in the Journal of the Ministry of Health of the Czech Republic .
Ischemic cerebrovascular events (iCMP) make up 88% of all CMPs, in the Czech Republic the incidence of iCMP is currently 211 cases per 100,000 inhabitants per year and the prevalence is estimat...
Atrial fibrillation (AF) is the most common cardiac arrhythmia with a worldwide prevalence of approximately 2% (3, 4, 5). The occurrence of the disease depends on age, the prevalence among people under 60 years old is less than 1%, among people 80 years old and older it is 7...9%. Based on prevalence ind...
Macle, L;
Cairns, J;
Leblanc, K;
Tsang, T;
Skanes, A;
Cox, JL;
Healey, JS;
Bell, A;
Pilote, L;
Andrade, JG;
Mitchell, LB;
Atzema, C;
Gladstone, D;
Sharma, M;
Verma, S;
Connolly, S;
Dorian, P;
Parkash, R;
Talajic, M;
Nattel, S;
Verma, A.
The Canadian Cardiovascular Society (CCS) Atrial Fibrillation (AF) Guidelines Committee provides periodic reviews of new data to produce focused updates that address clinically important advances in AF management. This 2016 Focused Update deals with: (1) the management of antithrombotic therapy for AF pa...
Anticoagulantes,
Cardiotónicos,
Inhibidores de Agregación Plaquetaria,
Digoxina,
Magnesio,
Síndrome Coronario Agudo/terapia,
Algoritmos,
Anticoagulantes/uso terapéutico,
Apéndice Atrial/cirugía,
Fibrilación Atrial,
Estimulación Cardíaca Artificial,
Cardiotónicos/efectos adversos,
Ablación por Catéter,
Cardiotónicos/administración & dosificación,
Fibrilación Atrial/terapia,
Fibrilación Atrial/complicaciones,
Hemorragia/inducido químicamente,
Hemorragia/prevención & control,
Magnesio/uso terapéutico,
Intervención Coronaria Percutánea,
Inhibidores de Agregación Plaquetaria/uso terapéutico,
Complicaciones Posoperatorias/prevención & control,
Infarto del Miocardio con Elevación del ST/terapia,
Accidente Cerebrovascular/prevención & control,
Enfermedad de la Arteria Coronaria/complicaciones,
Digoxina/administración & dosificación,
Digoxina/efectos adversos,
Quimioterapia Combinada,
Inhibidores del Factor Xa/uso terapéutico,
Fibrinolíticos/uso terapéutico,
Inhibidores del Factor Xa
El objetivo fundamental de este documento es establecer recomendaciones, basadas en criterios de eficacia, seguridad y eficiencia, para la elección del tratamiento anticoagulante destinado a la prevención de las complicaciones tromboembolias asociadas a la fibrilación auricular no valvula....
